Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

The immune system is the collective army of a trillion white blood cells, the bone marrow, antibodies and the thymus gland that identifies and then destroys the millions of microbes (bacteria, viruses, parasites, fungi) that penetrate our bodies every day. This system also needs to eliminate 500 to 10,000 of our own cells that have become genetically abnormal or cancerous. ———

Central to the immune system are the lymphocytes which include the T-cells, B-cells and NK cells. These cells are able to identify and destroy almost every intruder or infected/cancerous cell in the body. NK cells are of particular importance because they are able to work more or less independently, without special instructions from the immune system, to recognize and destroy many types of cancerous cells. ———
They are therefore considered the body’s first line of defense against cancer.~ canceractive

https://pubmed.ncbi.nlm.nih.gov/1311995/

VASOACTIVE INTESTINAL PEPTIDE AND REGULATORY T-CELL INDUCTION: A NEW MECHANISM AND THERAPEUTIC POTENTIAL FOR IMMUNE HOMEOSTASIS

https://pubmed.ncbi.nlm.nih.gov/17467339/

T cells are a part of the immune system that focuses on specific foreign particles. Rather than generically attack any antigens, T cells circulate until they encounter their specific antigen. As such, T cells play a critical part in immunity to foreign substances.

https://www.news-medical.net/health/What-are-T-Cells.aspx

WE’VE FINALLY ARRIVED: ZYESAMI

These studies indicate that altered VIP concentration can have significant consequences in terms of health and disease. In addition, the protective effects of VIP from tissue damage associated with inflammatory processes described in the lung also may be applicable to other pathological conditions such as rheumatoid arthritis, anaphylaxis, and the swelling and edema seen in the brain following head trauma. While VIP degrades rapidly, synthetic VIP-like drugs may be developed that interact with VIP receptors and have similar protective effects. Synthetic VIP-like agents also may be useful in treating neuroendocrine disorders associated with dysregulation of the hypothalamic-pituitary-adrenal axis, and pituitary release of prolactin.

https://pubmed.ncbi.nlm.nih.gov/8790778/

VIP RESTORES NATURAL KILLER CELL ACTIVITY DEPRESSED BY HEPATITIS B SURFACE ANTIGEN

https://pubmed.ncbi.nlm.nih.gov/1418317/

Natural killer (NK) cells are effector lymphocytes of the innate immune system that control several types of tumors and microbial infections by limiting their spread and subsequent tissue damage.

https://www.nature.com/articles/ni1582

NK CELLS WITH ADAPTIVE IMMUNE CELL PROPERTIES ———

Classically, NK cells are regarded as members of the innate immune system, but recent studies have elucidated that NK cells can display both adaptive and memory-like phenotypes. Antigen-specific NK cell memory was first described in T and B cell deficient mice displaying hapten-specific contact hypersensitivity (CHS) in skin cells after adoptive transfer of NK cells from a previously sensitized donor (O'Leary et al., 2006).

https://www.frontiersin.org/articles/10.3389/fcimb.2020.00231/full

POTENTIAL TO BECOME TIL and/or ONCOLOGY IMMUNOTHERAPEUTIC???

VASOACTIVE INTESTINAL PEPTIDE INCREASES APOPTOSIS OF HEPATOCELLULAR CARCINOMA BY INHIBITING THE cAMP /Bcl- xL PATHWAY ———

Studies have revealed expression of VIP receptors in several human carcinomas, including HCC, and in vitro studies have shown that VIP inhibits proliferation of hepatoma and glioma cells. However, the mechanisms by which VIP modulates HCC pathogenesis remain unknown. In the study described herein, we confirmed expression of VIP in HCC tissues, and we showed the effects of VIP in the Huh7 HCC cell line in vitro.

https://www.proquest.com/docview/2328376579

THE GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE WAS ESTIMATED AT USD 91.0 BILLION IN 2019 AND IS EXPECTED TO REACH USD 107.3 BILLION IN 2020

https://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-market